- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00507884
Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors
The goal of this clinical research study is to find out if "3 Tesla" MRI is as good as CT scan in the evaluation of kidney tumor(s).
Objectives:
To provide preliminary data to enable subsequent development of an MRI protocol at 3 Tesla for evaluation of renal tumors and their vascular supply, which can be adopted in patients who are unable to undergo CT evaluation.
Study Overview
Detailed Description
"3 Tesla" MRI is a new MRI scanner that in theory, can produce better images than currently available MRI scanners.
Currently, CT scanning is the main way of evaluating tumors in the kidneys. However, there are some patients who cannot have CT scans (usually, because of allergy to CT contrast medium or kidney damage/failure). It is with these patients that researchers are hoping to use a technique (using MRI) that is as good as CT scanning.
As part of your standard of care, your doctor is requesting a CT scan of your kidneys and abdomen. If you take part in this study, you will have a "3 Tesla" MRI scan of your kidneys and abdomen as well, within 15 days following your routine CT.
For the "3 Tesla" MRI scan, you will be lying flat on the MRI scanner, and as with a regular scan, you will have a small needle placed in a vein in your arm to inject the contrast dye. A diuretic, Lasix, will be given to help distend the internal tubes in the kidney to help view your kidney better. The MRI scan will take between 1-2 hours to perform. As with regular scans, you may be asked to hold your breath on occasions.
If there is a concern about your kidney function, blood (about 1 teaspoon) will be drawn to test your kidney function before you have the MRI.
Your participation in the study will be complete at the end of the MRI scan. The routine CT scan will be the main decision making examination. However, if the MRI shows something different and potentially relevant to your care, your referring physician will be informed.
This is an investigational study. A total of 45 patients will take part in this study. All will be enrolled at MD Anderson.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who have undergone or are due to undergo a CT Renal Protocol study, in the course of pre-operative evaluation for renal tumor surgery.
- Written informed consent will be obtained.
Exclusion Criteria:
- Patients with an allergy to both gadopentetate dimeglumine and gadodiamide MRI contrast agents.
- Patients with certain metallic implants, e.g., cardiac pacemakers, cardiac defibrillators, aneurysm clips, neurostimulators, and certain metallic foreign bodies. Implanted medical devices must be MRI compatible at 3.0 Tesla field strengths.
- Patients with claustrophobia, or requiring sedation for the MRI scan.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
3 Tesla MRI
Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
|
MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Comparison of CT and MRI scans of patients with renal cell carcinoma in evaluating each of nine imaging variables.
Time Frame: 4 Years
|
4 Years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chaan Ng, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2004-0875
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Neoplasms
-
St. Petersburg State Pavlov Medical UniversitySaint Petersburg State University, RussiaCompleted
-
Philips HealthcareWithdrawnKidney TumorsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedKidney TumorUnited States
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Thomas MuellerUnknownKidney Neoplasms | Adult Polycystic Kidney Disease | Kidney DysfunctionSwitzerland
-
Intuitive SurgicalCompleted
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting
Clinical Trials on 3 Tesla MRI Scan
-
Radboud University Medical CenterUnknown
-
Centre Francois BaclesseActive, not recruitingProton Therapy | Benign Brain TumorsFrance
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingProstate CarcinomaUnited States
-
University of Texas Southwestern Medical CenterCancer Prevention Research Institute of TexasCompletedMalignant Gliomas | Astrocytomas | OligodendrogliomasUnited States
-
Rennes University HospitalCompletedIron Hepatic Overload | Fat Hepatic OverloadFrance
-
University Hospital Inselspital, BerneRecruitingCerebral Small Vessel Diseases | Intracerebral Hemorrhage | CAA - Cerebral Amyloid AngiopathySwitzerland
-
University of Texas Southwestern Medical CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Gliomas | Astrocytomas | OligodendrogliomasUnited States
-
AHS Cancer Control AlbertaCompleted
-
Sunnybrook Health Sciences CentrePhilips HealthcareCompletedProstate CancerCanada
-
Hadassah Medical OrganizationNot yet recruitingStroke | Anosognosia | Acute Inflammatory Demyelinating Polyradiculoneuropathy | Central and Peripheral Neurodegenerative Pathologies | Neuropsychiatric Conditions